Molecular Partners Ag (MOLN) Change in Cash (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Change in Cash of -$23499.4 for Q1 2026, down 220.74% year-over-year from $19462.2 in Q1 2025, and down 100.1% quarter-over-quarter from $23.5 million in Q4 2025.
Molecular Partners Ag (MOLN) Change in Cash (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Change in Cash for 7 consecutive years, with -$23499.4 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash fell 220.74% year-over-year to -$23499.4; the TTM figure through Mar 2026 stood at $22.7 million (up 23474.75% YoY), while the FY2025 annual figure was $23.5 million, up 699.21% from the prior year.
- Change in Cash retreated to -$23499.4 in Q1 2026 per MOLN's latest filing, from $23.5 million in the prior quarter.
- Across five years, Change in Cash topped out at $44.7 million in Q2 2022 and bottomed at -$44.7 million in Q3 2022.
- Historically, Change in Cash has averaged $1.1 million across 5 years, with a median of $10324.5 in 2024.
- On a YoY basis, Change in Cash climbed as much as 1539.71% in 2025 and fell as far as 1308.69% in 2025.
- Molecular Partners Ag's Change in Cash stood at $16.7 million in 2022, then sank by 238.78% to -$23.2 million in 2023, then surged by 108.05% to $1.9 million in 2024, then surged by 1155.0% to $23.5 million in 2025, then slumped by 100.1% to -$23499.4 in 2026.
- Business Quant data shows MOLN's Change in Cash at -$23499.4 in Q1 2026, $23.5 million in Q4 2025, and -$22.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | -23,499.44 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23,499.44 |
| Dec 31, 2025 | 23.47 Mn |
| Sep 30, 2025 | -22.61 Mn |
| Jun 30, 2025 | 21.84 Mn |
| Mar 31, 2025 | 19,462.16 |
| Sep 30, 2024 | 1.87 Mn |
| Jun 30, 2024 | -1.79 Mn |
| Mar 31, 2024 | 1,186.93 |
| Dec 31, 2023 | -23.24 Mn |
| Sep 30, 2023 | 27.95 Mn |
| Jun 30, 2023 | -27.46 Mn |
| Mar 31, 2023 | -15,153.57 |
| Dec 31, 2022 | 16.75 Mn |
| Sep 30, 2022 | -44.66 Mn |
| Jun 30, 2022 | 44.71 Mn |
| Mar 31, 2022 | 76,019.64 |
| Dec 31, 2021 | -67.08 Mn |
| Sep 30, 2021 | 7.74 Mn |
| Jun 30, 2021 | -7.82 Mn |
| Mar 31, 2021 | -30,471.93 |